Telemedicine and Clinical Outcomes in Peritoneal Dialysis: A Propensity-Matched Study
Xiao Xu,Tiantian Ma,Xue Tian,Shaomei Li,Huaying Pei,Jinghong Zhao,Ying Zhang,Zibo Xiong,Yumei Liao,Ying Li,Qiongzhen Lin,Wenbo Hu,Yulin Li,Zhaoxia Zheng,Liping Duan,Gang Fu,Shanshan Guo,Beiru Zhang,Rui Yu,Fuyun Sun,Xiaoying Ma,Li Hao,Guiling Liu,Zhanzheng Zhao,Jing Xiao,Yulan Shen,Yong Zhang,Xuanyi Du,Tianrong Ji,Caili Wang,Lirong Deng,Yingli Yue,Shanshan Chen,Zhigang Ma,Yingping Li,Li Zuo,Huiping Zhao,Xianchao Zhang,Xuejian Wang,Yirong Liu,Xinying Gao,Xiaoli Chen,Hongyi Li,Shutong Du,Cui Zhao,Zhonggao Xu,Li Zhang,Hongyu Chen,Li,Lihua Wang,Yan,Yingchun Ma,Yuanyuan Wei,Jingwei Zhou,Yan Li,Yingdong Zheng,Jinwei Wang,Minghui Zhao,Jie Dong
DOI: https://doi.org/10.1159/000525917
2022-01-01
American Journal of Nephrology
Abstract:INTRODUCTION:Telemedicine (TM) has shown to provide potential benefits on clinical outcomes in patients with chronic kidney disease but limited evidences published in the peritoneal dialysis (PD) population. This study aimed to explore the long-term effects of TM on the mortality and technique failure.METHODS:The Peritoneal Dialysis Telemedicine-assisted Platform Cohort Study (PDTAP Study) was conducted prospectively in 27 hospitals in China since 2016. Patient and practice data were collected through the doctor-end of the TM app (Manburs) for all participants. TM including self-monitoring records, on-line education materials, and real-time physician-patient contact was only performed for the patient-end users of the Manburs. The primary outcome was all-cause mortality. The secondary outcomes were cause-specific mortality and all-cause and cause-specific permanent transfer to hemodialysis.RESULTS:A total of 7,539 PD patients were enrolled between June 2016 and April 2019, with follow-up till December 2020. Patients were divided into two cohorts: TM group (39.1%) and non-TM group (60.9%). A propensity score was used to create 2,160 matched pairs in which the baseline covariates were well-balanced. There were significantly lower risks of all-cause mortality (HR 0.59 [0.51, 0.67], p < 0.001), CVD mortality (HR 0.59 [0.49, 0.70], p < 0.001), all-cause transfer to hemodialysis (0.57 [0.48, 0.67], p < 0.001), transfer to hemodialysis from PD-related infection (0.67 [0.51, 0.88], p = 0.003), severe fluid overload (0.40 [0.30, 0.55], p < 0.001), inadequate solute clearance (0.49 [0.26, 0.92], p = 0.026), and catheter-related noninfectious complications (0.41 [0.17, 0.97], p = 0.041) in the TM group compared with the non-TM group.CONCLUSION:This study indicated real-world associations between TM usage and reduction in patient survival and technique survival through a multicenter prospective cohort.